IS (@Sen60000) profile picture
Joined September 2024
Baker Brothers added a new position in $TERN last quarter. This week, Merck announced they're acquiring Terns for $6.7B. Here's what else Baker Bros was buying — and the catalysts coming in the next 90 days 🧵
2
4
302
TL;DR: Baker Bros' biggest new adds have 3 PDUFA dates in the next 8 months: • $CELC — Jul 17 • $SMMT — Nov 14 • $KYMR — data TODAY Their last new position ($TERN) got acquired by Merck 3 months later. Which of these names are you watching?
1
1
426
1/ 🧵 Seven specialist biotech funds are piling into the same stock. Four of them have been building for a year — and they're still adding. $PRAX (Praxis Precision Medicine) Here's the full playbook, quarter by quarter 👇
1
1
108
9/ You can't see this in a single 13F. One quarter shows a position. Four quarters show a playbook: initiate early, build conviction, add after the data confirms, never sell. We track 15 specialist biotech funds across 4 quarters. Free weekly brief every Monday.
1
35
Baker Bros manages $22B and is one of the most successful biotech-specialist funds in history. Their Q4 2025 13F just dropped. 85 holdings. 74% concentrated in top 10. They don't diversify — they concentrate on high-conviction bets. Here are the moves that matter:
1
80
$TERN — NEW POSITION (Q4 2025) Terns Pharmaceuticals: allosteric BCR-ABL inhibitor for CML. Phase 1 CARDINAL data (Dec 2025): 75% major molecular response at week 24 — more than double Novartis' Scemblix. Three months later: Merck acquires for $53/share ($6.7B).
185